Towards Personalization in the Curative Treatment of Gastric Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2020 Dec 17

PMID 33330111

Citations 6

Authors

Astrid E Slagter

Marieke A Vollebergh

Edwin P M Jansen

Johanna W van Sandick

Annemieke Cats

Nicole C T van Grieken

Marcel Verheij

Affiliations

Soon will be listed here.

Abstract

Gastric cancer is the fifth most common cancer worldwide and has a high mortality rate. In the last decades, treatment strategy has shifted from an exclusive surgical approach to a multidisciplinary strategy. Treatment options for patients with resectable gastric cancer as recommended by different worldwide guidelines, include perioperative chemotherapy, pre- or postoperative chemoradiotherapy and postoperative chemotherapy. Although gastric cancer is a heterogeneous disease with respect to patient-, tumor-, and molecular characteristics, the current standard of care is still according to a one-size-fits-all approach. In this review, we discuss the background of the different treatment strategies in resectable gastric cancer including the current standard, the specific role of radiotherapy, and describe the current areas of research and potential strategies for personalization of therapy.

Citing Articles

Construction and validation of a TTN mutation associated immune prognostic model for evaluating immune microenvironment and outcomes of gastric cancer: An observational study.

Chen R, Yao Z, Jiang L Medicine (Baltimore). 2024; 103(29):e38979.

PMID: 39029079 PMC: 11398786. DOI: 10.1097/MD.0000000000038979.

Treatment Outcomes and Prognostic Factors in N3 Stage Gastric Cancer After Curative Resection: A Real World Data.

Caliskan Yildirim E, Acikgoz Y, Ergun Y, Algin E, Bal O Cancer Manag Res. 2023; 15:1085-1096.

PMID: 37809035 PMC: 10559796. DOI: 10.2147/CMAR.S412270.

Flavonoid-Rich Extract of Oldenlandia diffusa (Willd.) Roxb. Inhibits Gastric Cancer by Activation of Caspase-Dependent Mitochondrial Apoptosis.

Ling J, Wang Q, Liang H, Liu Q, Yin D, Lin L Chin J Integr Med. 2022; 29(3):213-223.

PMID: 36044114 DOI: 10.1007/s11655-022-3679-4.

Prognostic value of tumor markers and ctDNA in patients with resectable gastric cancer receiving perioperative treatment: results from the CRITICS trial.

Slagter A, Vollebergh M, Caspers I, van Sandick J, Sikorska K, Lind P Gastric Cancer. 2021; 25(2):401-410.

PMID: 34714423 PMC: 8882113. DOI: 10.1007/s10120-021-01258-6.

The emerging role of miR-10 family in gastric cancer.

Liu F, Shi Y, Liu Z, Li Z, Xu W Cell Cycle. 2021; 20(15):1468-1476.

PMID: 34229543 PMC: 8354661. DOI: 10.1080/15384101.2021.1949840.

References

Morishima T, Matsumoto Y, Koeda N, Shimada H, Maruhama T, Matsuki D . Impact of Comorbidities on Survival in Gastric, Colorectal, and Lung Cancer Patients. J Epidemiol. 2018; 29(3):110-115. PMC: 6375811. DOI: 10.2188/jea.JE20170241. View

Ajani J, Winter K, Okawara G, Donohue J, Pisters P, Crane C . Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol. 2006; 24(24):3953-8. DOI: 10.1200/JCO.2006.06.4840. View

Bajetta E, Floriani I, Di Bartolomeo M, Labianca R, Falcone A, Di Costanzo F . Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. Ann Oncol. 2014; 25(7):1373-1378. DOI: 10.1093/annonc/mdu146. View

Cunningham D, Allum W, Stenning S, Thompson J, van de Velde C, Nicolson M . Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006; 355(1):11-20. DOI: 10.1056/NEJMoa055531. View

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

Choi Y, Kim H, Shin S, Kim H, Lee J, Yang H . Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer: Post Hoc Analysis of the CLASSIC Randomized Controlled study. Ann Surg. 2018; 270(2):309-316. DOI: 10.1097/SLA.0000000000002803. View

. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 2020; 24(1):1-21. PMC: 7790804. DOI: 10.1007/s10120-020-01042-y. View

Yao J, Schnirer I, Reddy S, Chiang S, Najam A, Yu C . Effects of sex and racial/ethnic group on the pattern of gastric cancer localization. Gastric Cancer. 2002; 5(4):208-12. DOI: 10.1007/s101200200036. View

Shitara K, Van Cutsem E, Bang Y, Fuchs C, Wyrwicz L, Lee K . Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020; 6(10):1571-1580. PMC: 7489405. DOI: 10.1001/jamaoncol.2020.3370. View

10.

Lee K, Oh D, Han M, Lee H, Jun J, Choi K . Gastric cancer screening in Korea: report on the national cancer screening program in 2008. Cancer Res Treat. 2011; 43(2):83-8. PMC: 3138921. DOI: 10.4143/crt.2011.43.2.83. View

11.

Smyth E, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D . Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016; 27(suppl 5):v38-v49. DOI: 10.1093/annonc/mdw350. View

12.

Smyth E, Wotherspoon A, Peckitt C, Gonzalez D, Hulkki-Wilson S, Eltahir Z . Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial. JAMA Oncol. 2017; 3(9):1197-1203. PMC: 5824280. DOI: 10.1001/jamaoncol.2016.6762. View

13.

Qiu M, Cai M, Zhang D, Wang Z, Wang D, Li Y . Clinicopathological characteristics and prognostic analysis of Lauren classification in gastric adenocarcinoma in China. J Transl Med. 2013; 11:58. PMC: 3600019. DOI: 10.1186/1479-5876-11-58. View

14.

Asplund J, Kauppila J, Mattsson F, Lagergren J . Survival Trends in Gastric Adenocarcinoma: A Population-Based Study in Sweden. Ann Surg Oncol. 2018; 25(9):2693-2702. PMC: 6097732. DOI: 10.1245/s10434-018-6627-y. View

15.

Park S, Sohn T, Lee J, Lim D, Hong M, Kim K . Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses. J Clin Oncol. 2015; 33(28):3130-6. DOI: 10.1200/JCO.2014.58.3930. View

16.

Tashiro H, Brenner M . Immunotherapy against cancer-related viruses. Cell Res. 2016; 27(1):59-73. PMC: 5223233. DOI: 10.1038/cr.2016.153. View

17.

Becker K, Langer R, Reim D, Novotny A, Zum Buschenfelde C, Engel J . Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. Ann Surg. 2011; 253(5):934-9. DOI: 10.1097/SLA.0b013e318216f449. View

18.

van der Kaaij R, Snaebjornsson P, Voncken F, van Dieren J, Jansen E, Sikorska K . The prognostic and potentially predictive value of the Laurén classification in oesophageal adenocarcinoma. Eur J Cancer. 2017; 76:27-35. DOI: 10.1016/j.ejca.2017.01.031. View

19.

Bonenkamp J, Songun I, Hermans J, Sasako M, Welvaart K, Plukker J . Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet. 1995; 345(8952):745-8. DOI: 10.1016/s0140-6736(95)90637-1. View

20.

Songun I, Putter H, Meershoek-Klein Kranenbarg E, Sasako M, van de Velde C . Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010; 11(5):439-49. DOI: 10.1016/S1470-2045(10)70070-X. View